Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.50 |
| ▸ | CDK2 | P24941 | 9/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.50 |
| ▸ | AURKA | O14965 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 8/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 8/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21255655 | 0.85 | MAPK1 (0.56) | MAPK1EP300CREBBPBRD4BAZ2B | |
| SCHEMBL2387629 | 0.84 | CCNA2 (0.39) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL16123821 | 0.81 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL23642304 | 0.79 | CCNA2 (0.50) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL12057801 | 0.77 | CCNA2 (0.61) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL22958076 | 0.76 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL2922187 | 0.76 | CCNA2 (0.67) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17785865 | 0.73 | CREBBP (0.44) | MAPK1EP300CREBBPBRD4 | |
| SCHEMBL2923652 | 0.72 | CCNA2 (0.38) | CCNA2CDK2CCNA1AURKAMAPK1 | |
| SCHEMBL2913589 | 0.72 | CCNA2 (0.63) | CCNA2CDK2CCNA1AURKAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928456-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8273765-B2 | Bicyclo-pyrazoles and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2012-09-25 | — | — | US | disclosed |
| US-8114870-B2 | Method of treating disease states using substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114870-B2 | Method of treating disease states using substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | PFIZER ITALIA S.R.L. (IT) | 2009-09-03 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007041358-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142368-A1 | Substituted pyrazole compounds | AURKC, AURKA, AURKB | CCNA2 267/4885CDK2 11/4885CCNA1 694/4885 |
| US-20090264422-A1 | METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | CCNA2 333/4885CDK2 26/4885CCNA1 940/4885 |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | CCNA2 848/4885CDK2 43/4885CCNA1 793/4885 |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | MAP3K20, PLK2, PRKAA1 | CCNA2 1043/4885CDK2 70/4885CCNA1 1090/4885 |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | CCNA2 848/4885CDK2 43/4885CCNA1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.